Articles

O.6 Long-term survival in patients receiving rhEPO following allogeneic hematopoietic cell transplantation

BJH - volume 5, issue Abstract Book BHS, january 2014

A. Jaspers MD, PhD, prof. F. Baron , E. Willems MD, PhD, K. Hafraoui , C. Bonnet MD, Y. Beguin MD, PhD

Read more

P1.08 Hemolytic crisis induced by rasburicase administration revealing G-6-PD deficiency

BJH - volume 5, issue Abstract Book BHS, january 2014

S. Sid MD, D. Dugauquier , B. De Prijck MD, C. Bonnet MD, Y. Beguin MD, PhD

Read more

O.1 ABVD (8 cycles) vs. BEACOPP (4 escalated cycles => 4 baseline) in stage III – IV low risk Hodgkin Lymphoma (IPS 0–2): final results of LYSA H34 trial

BJH - volume 5, issue Abstract Book BHS, january 2014

M. André MD, PhD, B. De Prijck MD, A. Kentos MD, PhD, A. Van Hoof MD, PhD, C. Bonnet MD, A. Sonet MD, M. Maerevoet MD, E. Van den Neste MD, PhD, A. Bosly MD, PhD, N. Mounier

Read more

Treatment of peripheral T-cell lymphomas: recommendations of the Belgian Hematological Society (BHS)

BJH - volume 4, issue 3, september 2013

F. Van Obbergh MD, A. Van Hoof MD, PhD, G. Verhoef MD, PhD, D. Dierickx MD, PhD, V. De Wilde MD, PhD, F. Offner MD, PhD, D. Bron MD, PhD, A. Sonet MD, M. André MD, PhD, A. Janssens MD, PhD, C. Bonnet MD, B. Deprijck MD, P. Zachée MD, PhD, A. Kentos MD, PhD, W. Schroyens MD, PhD, E. Van den Neste MD, PhD

Summary

The sub-committee on lymphoproliferative disorders of the Belgian Hematological Society has met several times to prepare guidelines on the management of patients with peripheral T-cell lymphomas. Each panellist’s expert provided interpretation of the evidence, based on literature review and personal experience. The available evidence was systematically discussed prior to formulating recommendations. A systematic approach to obtain consensus of expert opinion was used. After each meeting, the draft guideline was circulated to all experts for comment and approval. The present guidelines focus on general management of peripheral T-cell lymphomas with special emphasis on more specific disease-adapted strategies.

(BELG J HEMATOL 2013;4(3):90–101)

Read more

Guidelines for newly diagnosed diffuse large B-cell lymphoma (DLBCL) and relapsed DLBCL

BJH - volume 4, issue 2, june 2013

G. Verhoef MD, PhD, W. Schroyens MD, PhD, D. Bron MD, PhD, C. Bonnet MD, V. De Wilde MD, PhD, A. Van Hoof MD, PhD, A. Janssens MD, PhD, D. Dierickx MD, PhD, M. André MD, PhD, E. Van den Neste MD, PhD

Summary

The guidelines for adult patients in this article are based on 2011 ESMO and NCCN version 4.2011 guidelines and amended for the particular Belgian context of label prescription and reimbursement. Levels of evidence for the use of treatment recommendations are given in square brackets. Statements without grading were considered justifed standard clinical practice by the experts of the BHS-lymphoma working party.

(BELG J HEMATOL 2013;4(2):51–57)

Read more

O.7 Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomised trial

BJH - 2013, issue BHS Abstractbook, january 2013

A. Jaspers MD, PhD, prof. F. Baron , E. Willems MD, PhD, K. Hafraoui , G. Vanstraelen , C. Bonnet MD, Y. Beguin MD, PhD

Read more

P.39 Simultaneous diagnosis of CLL and CML in a single patient with evidence for two different cell clones

BJH - 2013, issue BHS Abstractbook, january 2013

C. Bonnet MD, C. Menten PhD, F. Lambert MD, A. Gothot MD, PhD, prof. F. Baron , J. Caers MD, PhD, C. Herens , Y. Beguin MD, PhD

Read more